Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
Jasmin ElurbideLeticia ColynMaria U LatasaIker UriarteStefano MarianiAmaya López-PascualEmiliana ValbuenaBorja Castello-UribeRobert Arnes-BenitoElena Adan-VillaescusaLuz Andrea Martínez-PérezMikel AzkargortaFelix ElortzaHanghang WuMarcin KrawczykKai Markus SchneiderBruno SangroLuca AldrighettiFrancesca RattiAndrea Casadei GardiniJose J G MarinIrene AmatJesus M UrmanMaría ArechederraMaría Luz Martínez-ChantarChristian TrautweinMeritxell HuchFrancisco Javier CuberoCarmen BerasainMaite G Férnandez-BarrenaMatias A AvilaPublished in: Gut (2024)
PRMT5 and MEP50 are frequently upregulated in human CCA, and PRMT5-targeting drugs have significant antitumoural efficacy in clinically relevant CCA models. Our findings support the evaluation of PRMT5 inhibitors in clinical trials, including their combination with cytotoxic and immune therapies.